Tag Archive for: #Synaffix

Synaffix Licenses Metal-Free Click Chemistry Technology to Illumina for Next-Generation DNA Sequencing Applications

/in

Agreement grants access to Synaffix patent portfolio related to metal-free click chemistry Technology to be used in Illumina’s next-generation sequencing (NGS) products AMSTERDAM, THE NETHERLANDS, 4 December 2024 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage bioconjugation platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index and […]

Read more

Lonza’s Synaffix Collaborates with BigHat Biosciences on the Development of a Machine Learning-Designed ADC

/in

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores Lonza’s commitment to helping customers deliver innovative new therapies to patients by offering a comprehensive service offering for differentiated ADCs BigHat’s artificial intelligence (AI)/machine learning (ML)-powered antibody design platform, Milliner™ was used to design a highly differentiated […]

Read more

Optimum’s Year-End Review  

/in

2023 was an exciting year for Optimum’s clients who overcame many of the market challenges to make significant strides forward with their vital life sciences research. Here are some of the highlights from what has been an exceptionally busy and successful year.   M&A & deals Synaffix continued to build momentum – Lonza acquired the […]

Read more

Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study

/in

New deal builds on encouraging preliminary clinical data from the Phase 1 study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021 The expanded collaboration to provide Innovent with access to additional targets and further proprietary Synaffix linker-payloads for the development of additional innovative ADCs  Synaffix will be eligible to […]

Read more

SOTIO Enters Licensing Agreement With Synaffix to Expand ADC Pipeline

/in

Synaffix to provide access to proprietary Antibody-Drug Conjugate (ADC) technologies  SOTIO to develop up to three next generation bioconjugates  Total potential deal value of up to $740 million, plus royalties on commercial sales for three ADC programs  AMSTERDAM, THE NETHERLANDS, 16 September 2023 — Synaffix B.V., a Lonza company (SIX:LONN) focused on commercializing its clinical-stage […]

Read more